Study Findings May Lead To Earlier Diagnosis And Treatment Of Atherosclerosis

November 11, 1997

PITTSBURGH, Nov. 11 -- Earlier diagnosis and treatment of atherosclerosis may be possible using specially engineered, gas-filled microbubbles, according to a study by researchers at the University of Pittsburgh Medical Center (UPMC).

The study will be presented Nov. 11 by Flordeliza S. Villanueva, M.D., assistant professor of medicine in the division of cardiology, at the annual scientific session of the American Heart Association in Orlando, Fla.

Microbubbles, gas-filled microspheres the size of red blood cells, are used in contrast echocardiography, an ultrasound technique used to detect blood flow to the heart muscle in conditions such as angina or heart attack.

One of the first processes leading to atherosclerosis involves the inflammation of the endothelial cells which line blood vessels. The researchers wanted to find a way to identify these abnormal endothelial cells which are harbingers of atherosclerosis. To simulate the inflammation which occurs on endothelial cells during early atherosclerosis, cultured endothelial cells were experimentally stimulated to produce a protein on their surface called ICAM-1. ICAM-1 is thought to be centrally involved in the development of atherosclerosis.

"Currently, we have no techniques for identifying this potentially reversible, major change in endothelial cells in humans," Dr. Villanueva said.

The study, performed in collaboration with William Wagner, Ph.D., assistant professor of surgery and chemical engineering at the UPMC's McGowan Center for Artificial Organ Development, attempted to develop contrast echocardiography as a method to study this very early abnormality which occurs in patients who subsequently develop coronary artery disease.

In their study, the researchers cultured human coronary artery endothelial cells on lab coverslips. Three types of microbubbles were made; one containing anti-human ICAM-1 monoclonal antibody, one with non-specific murine immunoglobulin, and one with no added proteins.

Some of the endothelial cells were stimulated by interleukin-1 while others were not. Both groups were then exposed to one of the microbubble preparations. Researchers then counted the number of microbubbles which bound to the endothelial cells.

According to the study, binding of microbubbles to normal endothelial cells was minimal, however, there was a 40-fold increase in adherence of the microbubbles containing anti-ICAM-1 to the activated endothelial cells. These adherent microbubbles can then be detected using ultrasound imaging (echocardiography).

"This may allow us to localize an area of the artery where atherosclerosis is just developing so that we can intervene at a much earlier disease stage than is currently possible," said Dr. Wagner.

For additional information about the University of Pittsburgh Medical Center, please access http://www.upmc.edu.
-end-


University of Pittsburgh Medical Center

Related Atherosclerosis Articles from Brightsurf:

How hormone therapy slows progression of atherosclerosis
As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis.

T cells can shift from helping to harming in atherosclerosis
At La Jolla Institute for Immunology (LJI) researchers are dedicated to finding a way to stop plaques from forming in the first place.

New nanoparticle drug combination for atherosclerosis
Physicochemical cargo-switching nanoparticles (CSNP) designed by KAIST can help significantly reduce cholesterol and macrophage foam cells in arteries, which are the two main triggers for atherosclerotic plaque and inflammation.

Atherosclerosis -- How a microRNA protects vascular integrity
Ludwig-Maximilian-Universitaet (LMU) in Munich researchers have discovered a hitherto unknown molecular function of a specific microRNA that preserves integrity of the endothelium and reduces the risk of atherosclerosis.

Atherosclerosis progresses rapidly in healthy people from the age of 40
A CNIC study published in JACC demonstrates that atheroma plaques extend rapidly in the arteries of asymptomatic individuals aged between 40 and 50 years participating in the PESA-CNIC-Santander study.

Scaling up a nanoimmunotherapy for atherosclerosis through preclinical testing
By integrating translational imaging techniques with improvements to production methods, Tina Binderup and colleagues have scaled up a promising nanoimmunotherapy for atherosclerosis in mice, rabbits and pigs -- surmounting a major obstacle in nanomedicine.

Bladder drug linked to atherosclerosis in mice
A drug used in the treatment of overactive bladder can accelerate atheroclerosis in mice, researchers at Karolinska Institutet in Sweden report in a study published in the Proceedings of the National Academy of Sciences (PNAS).

A new therapeutic target for blocking early atherosclerosis in progeria
Researchers at the Centro Nacional de Investigaciones Cardiovasculares and the Universidad de Oviedo have discovered a new molecular mechanism involved in the premature development of atherosclerosis in mice with Hutchinson-Gilford progeria syndrome.

Protective mechanism against atherosclerosis discovered
Immune cells promoting inflammation play a crucial role in the development of atherosclerosis.

Atherosclerosis: Stopped on time
For the first time, LMU researchers are pointing out the influence of the internal clock on atherosclerosis.

Read More: Atherosclerosis News and Atherosclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.